What happened?
A number of stocks jumped in the afternoon session after election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy.
As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions.
Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic. The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.
Among others, the following stocks were impacted:
- Medical devices & supplies - diversified company Stryker (NYSE: SYK) jumped 8.8%. Is now the time to buy Stryker? Access our full analysis report here, it’s free.
- Healthcare technology for providers company Omnicell (NASDAQ: OMCL) jumped 10.8%. Is now the time to buy Omnicell? Access our full analysis report here, it’s free.
- Surgical equipment & consumables - diversified company Zimmer Biomet (NYSE: ZBH) jumped 15.2%. Is now the time to buy Zimmer Biomet? Access our full analysis report here, it’s free.
- Medical devices & supplies - cardiology, neurology, vascular company Artivion (NYSE: AORT) jumped 9.1%. Is now the time to buy Artivion? Access our full analysis report here, it’s free.
- Dental equipment & technology company Dentsply Sirona (NASDAQ: XRAY) jumped 9.2%. Is now the time to buy Dentsply Sirona? Access our full analysis report here, it’s free.
Zooming in on Zimmer Biomet (ZBH)
Zimmer Biomet’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. Moves this big are rare for Zimmer Biomet and indicate this news significantly impacted the market’s perception of the business.
The biggest move we wrote about over the last year was 6 months ago when the stock gained 4.9% on the news that the company announced it increased its share repurchase expectations for fiscal year 2026. The medical device company now plans to buy back up to $1 billion of its common stock, a $250 million increase from its prior assumption. This action will be carried out under an existing $1.5 billion share repurchase authorization from February 2026.
A share buyback, or repurchase, is when a company buys its own shares from the marketplace. This reduces the number of shares available, which can increase the value of the remaining shares and often signals management's confidence that the stock is undervalued by the market.
Zimmer Biomet is up 24.4% since the beginning of the year, and at $111.96 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of Zimmer Biomet’s shares 5 years ago would now be looking at only $812.78.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
